ReviewCurrent hypertension reports2018
Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders.
Review in Current hypertension reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.BMC nephrology · 2022Pooled it
- Neuronal Sik1 in the Hypothalamic Paraventricular Nucleus Decreases Blood pressure Elevation Following a High-Salt Diet.Molecular neurobiology · 2026Article
- Potential causal associations between adiposity and hydration status in children and adolescents: evidence from negative control and Mendelian randomization analyses.Frontiers in nutrition · 2026Article
- Vasopressin Contributes to Respiratory and Cardiovascular Regulation in Spontaneously Hypertensive and Normotensive Rats.Journal of clinical medicine · 2025Article
- Blood Pressure Variability in Hypertension: A Rehabilitation Perspective.Journal of cardiovascular development and disease · 2025Review
- Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways.Current issues in molecular biology · 2025Review
- Beyond LDL-C: discordant small dense LDL cholesterol stratifies hypertension risk in a Chinese longitudinal cohort.Lipids in health and disease · 2025Article
- Impact of Angiotensin-Converting Enzyme Inhibitor on Coronary Artery Calcification Evaluated by Intravascular Ultrasound: A Retrospective Cohort Study.Health science reports · 2025Article
- Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues.ESC heart failure · 2025Review
- Copeptin Hormone Concentrations in Dogs with Heart Disease and Relationship with Antidiuretic Hormone.Animals : an open access journal from MDPI · 2025Article
- Mediterranean Diet as a Therapeutic Strategy for Hypertension and Cardiovascular Health.International journal of hypertension · 2025Review
- Molecular Interaction Between Vasopressin and Insulin in Regulation of Metabolism: Impact on Cardiovascular and Metabolic Diseases.International journal of molecular sciences · 2024Review
- PTSD Increases Risk for Hypertension Development Through PVN Activation and Vascular Dysfunction in Sprague Dawley Rats.Antioxidants (Basel, Switzerland) · 2024Article
- Role of local angiotensin II signaling in bladder function.American journal of physiology. Renal physiology · 2024Review
- Fine-tuning AMPK in physiology and disease using point-mutant mouse models.Disease models & mechanisms · 2024Review
- The Interaction of Vasopressin with Hormones of the Hypothalamo-Pituitary-Adrenal Axis: The Significance for Therapeutic Strategies in Cardiovascular and Metabolic Diseases.International journal of molecular sciences · 2024Review
- The central renin-angiotensin system: A genetic pathway, functional decoding, and selective target engagement characterization in humans.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Interplay of Angiotensin Peptides, Vasopressin, and Insulin in the Heart: Experimental and Clinical Evidence of Altered Interactions in Obesity and Diabetes Mellitus.International journal of molecular sciences · 2024Review
- Case report: Persistent syndrome of inappropriate antidiuresis after traumatic brain injury: spontaneous resolution and impact on RAAS and bone metabolism over five years.Frontiers in endocrinology · 2024Article
- Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.Biomolecules · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn many instances, the renin-angiotensin system (RAS) and the vasopressinergic system (VPS) are jointly activated by the same stimuli and engaged in the regulation of the same processes. RECENT
findingsAngiotensin II (Ang II) and arginine vasopressin (AVP), which are the main active compounds of the RAS and the VPS, interact at several levels. Firstly, Ang II, acting on AT1 receptors (AT1R), plays a significant role in the release of AVP from vasopressinergic neurons and AVP, stimulating V1a receptors (V1aR), regulates the release of renin in the kidney. Secondly, Ang II and AVP, acting on AT1R and V1aR, respectively, exert vasoconstriction, increase cardiac contractility, stimulate the sympathoadrenal system, and elevate blood pressure. At the same time, they act antagonistically in the regulation of blood pressure by baroreflex. Thirdly, the cooperative action of Ang II acting on AT1R and AVP stimulating both V1aR and V2 receptors in the kidney is necessary for the appropriate regulation of renal blood flow and the efficient resorption of sodium and water. Furthermore, both peptides enhance the release of aldosterone and potentiate its action in the renal tubules. In this review, we (1) point attention to the role of the cooperative action of Ang II and AVP for the regulation of blood pressure and the water-electrolyte balance under physiological conditions, (2) present the subcellular mechanisms underlying interactions of these two peptides, and (3) provide evidence that dysregulation of the cooperative action of Ang II and AVP significantly contributes to the development of disturbances in the regulation of blood pressure and the water-electrolyte balance in cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.